Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Theravance, Clinigen Ink Commercialization Agreement In EU For VIBATIV

RELATED NEWS
Trade THRX now with 

Clinigen Group plc (CLIN.L) and Theravance Inc. (THRX: Quote) have reached an exclusive commercialization agreement in the European Union or EU and certain other countries in Europe for VIBATIV to treat nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus or MRSA when other alternatives are not suitable.

VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

According to the deal, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV in the EU and some other European countries, including Switzerland and Norway. Theravance, in turn, would receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

Click here to receive FREE breaking news email alerts for THERAVANCE, INC. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With traders seemingly reluctant to make any significant moves, stocks are showing a lack of direction in early trading on Thursday. The major averages are lingering near the unchanged line after ending the previous session firmly in the red. First-time claims for U.S. unemployment benefits unexpectedly decreased in the week ended September 27th, according to a report released by the Labor Department on Thursday. The report said initial jobless claims fell to 287,000, a decrease of 8,000 from the previous week's revised level of 295,000. After ending the previous session sharply lower, stocks may see some further downside in early trading on Thursday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 31 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.